American Society of Hirudotherapy

Myofascial Pain Syndrome (Investigational Adjunct)

Investigational adjunct for chronic myofascial trigger-point pain; one small randomized trial (n=66) and Russian clinical series only; dry needling, manual therapy, and exercise remain primary.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 12, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for myofascial pain syndrome. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational.
What evidence exists?
Tier C (investigational). One small randomized trial (Ediz et al., 2021; 66 people with trapezius trigger-point pain) compared leech therapy with platelet-rich-plasma injection, both added to stretching exercises, and reported improvement in both groups with larger gains in the leech group; it had no placebo or untreated group, so it cannot show that leeches work better than no treatment. Russian clinical series from a 2004 monograph also report benefit but are brief conference reports. Evidence-based care: manual trigger-point release, dry needling (the strongest non-pharmacologic evidence for trigger-point pain), trigger-point injection with lidocaine, posture and ergonomic correction, graded exercise and stretching, treatment of mood and sleep comorbidities, and NSAIDs for short-term symptoms. Myofascial pain often coexists with cervical radiculopathy, lumbar pathology, fibromyalgia, or systemic inflammatory disease - workup distinguishes.
Main risks
  • Bleeding from each bite site for 6 to 24 hours after detachment
  • Bruising over the trigger-point area for 5 to 10 days
  • Local skin or, rarely, Aeromonas hydrophila infection
  • Allergic reaction to leech saliva (uncommon)
  • Temporary worsening of pain or muscle spasm for 1 to 3 days
  • Mild anemia with multiple repeated sessions across body regions
  • Delay of dry needling, manual therapy, and exercise - which have stronger evidence
  • Placebo response masking radiculopathy, systemic inflammatory disease, or fibromyalgia as underlying drivers
Who should not consider this
  • Patients with suspected cervical or lumbar radiculopathy pending imaging workup
  • Patients with suspected systemic inflammatory disorder (polymyalgia rheumatica, inflammatory myopathy)
  • Patients with primary fibromyalgia diagnosis (treated with widespread-pain protocol, not trigger-point)
  • Patients with red-flag features (fever, weight loss, night pain, cancer history)
  • Patients who have not tried at least 6 weeks of structured manual therapy and dry needling
  • Patients on anticoagulants, with hemophilia, or with anemia
  • Patients with active dermatitis or broken skin at planned placement sites
What to ask your clinician
  • Have we excluded cervical or lumbar radiculopathy, systemic inflammatory disease, and fibromyalgia?
  • Have I tried structured dry needling or trigger-point injection - both with more evidence?
  • Have I tried manual therapy, postural correction, ergonomic modification, and graded exercise?
  • Are mood, sleep, and stress being addressed - they drive chronic myofascial pain?
  • Where exactly will leeches be placed - confirm adjacent to (not directly on) trigger points?
  • What is the practitioner's plan if symptoms worsen?
  • What is the Aeromonas-prevention protocol?
When to seek urgent care
  • Sudden weakness, numbness, or radicular pain in an arm or leg
  • Bowel or bladder dysfunction, saddle anesthesia (cauda equina - 911)
  • Fever, weight loss, or night sweats with the pain
  • Severe worsening of pain unresponsive to usual measures
  • Bleeding from a bite site lasting more than 24 hours
  • Spreading redness, pus, or warmth at the bite site
  • Hives, facial or throat swelling, or breathing difficulty

What this does NOT mean

  • This is not FDA-cleared for myofascial pain syndrome.
  • One small randomized trial without a placebo or untreated arm does not establish efficacy; placebo response in chronic pain is substantial.
  • It does not replace dry needling, manual therapy, or graded exercise - which have stronger evidence.
  • It does not address underlying drivers (posture, ergonomics, deconditioning, sleep) that need correction.
  • Radiculopathy or systemic inflammatory disease must be excluded before any procedural intervention.

Clinical Profile

Category
Musculoskeletal
ICD-10
M79.18, M79.7
Safety tier
Low

Evidence Summary

Myofascial pain syndrome involves taut bands and trigger points in skeletal muscle causing referred regional pain. Evidence-based management includes manual trigger-point release, dry needling or trigger-point injection, posture and ergonomic correction, and graded exercise. The clinical evidence identified is one small randomized trial (Ediz et al., 2021, Eastern J Med): 66 people with trapezius trigger-point pain were randomized to leech therapy or platelet-rich-plasma injection, each added to 12 weeks of stretching exercises; pain scores fell significantly in both groups, pain threshold rose significantly only in the leech group, and SF-36 pain, general-health and vitality scores favored leeches. It had no placebo or untreated arm and was not found in PubMed or Europe PMC searches. Russian clinical series described in Baskova and Isakhanyan (2004) also report benefit (Krymskaya et al., 1999: 54 patients, leeches combined with novocaine and hydrocortisone infiltration; Frolov et al., 2003: 79 patients with myofascial pain of the foot and lower leg whose painful indurations persisted after manual therapy), but they are brief conference reports. Any use is investigational, and the proposed mechanism (local anti-inflammatory peptide effects and reflex muscle relaxation) is speculative. In chronic pain generally, lack of blinding and high placebo response tend to inflate apparent effect sizes, so uncontrolled observations should be interpreted with caution.

What the books describe

Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.

  • Baskova and Isakhanyan write (citing Krymskaya, Krymskaya, Gresko and colleagues, 1999) that myofascial pain syndrome is characterized by musculoskeletal and asthenovegetative (related to weakness, fatigue and the autonomic nervous system) disorders[B1].
  • They retell an observation by Krymskaya and colleagues (1999): 54 patients with myofascial indurations (painful hardenings in the muscles) were given hirudotherapy together with injections of novocaine and hydrocortisone into the tissues, and, as described, after the very first sessions the pain at the leech sites decreased or disappeared; no comparison group or follow-up period is named in the retelling, and it is not clear how to separate the effect of the leeches from the effect of the drugs[B1].
  • For myofascial pain in the foot and lower leg they cite an observation by Frolov, Frolova and Kartsev (2003): of 237 patients, 79 still had painful indurations after the first stage of treatment (manual therapy), and leeches were added for them; the retelling says that hirudotherapy combined with manual therapy and subsequent correction of the foot deformity produces a more marked reduction in pain than correction with manual therapy alone, but the sizes of the compared groups, the method of pain assessment and the follow-up period are not named, and it is not clear from the text whether there was a separate comparison group[B1].
  • Storck, in the chapter on rheumatic diseases in the book by Michalsen et al., writes that musculoskeletal pain syndromes with secondary muscle tension, zones of connective tissue hardening and myogelosis (local hardenings in a muscle) are a suitable indication for hirudotherapy, and that it is best combined with physical therapy and physical exercise; this summary statement gives no patient numbers and no references to studies[B3].
  • Michalsen, in Chapter 10, in the section “Degenerative diseases of other joints and myofascial pain syndrome,” writes that for myofascial pain syndrome the situation is much the same as for other joints, where there are no specific studies: low back pain and pain in the region of the iliosacral joint are often treated with leeches and, by subjective assessment, successfully, but there are no clinical study data, and the efficacy of hirudotherapy for such pain (as for lateral epicondylitis) cannot be assessed scientifically at present[B3].
  • Among the contraindications, Baskova and Isakhanyan name hemophilia, hemorrhagic diatheses, anemia, low blood pressure, acute vascular insufficiency (shock, collapse, fainting), exhaustion (cachexia), concurrent use of anticoagulants and alcohol, and individual intolerance; they advise refraining when body temperature is high, call the question of pregnancy open, and regard prescribing leeches in large numbers, for long periods, without breaks or with short breaks as unjustified and impermissible[B1].
  • Flecken and Michalsen (Chapter 8) call hemophilia and the use of anticoagulants an absolute contraindication, write that aspirin and clopidogrel are not in themselves a contraindication (in which case fewer leeches are needed at the first session), and that in anemia and in pregnancy treatment involving blood loss is, as a rule, contraindicated; this is only part of the contraindications listed in the books[B3].

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Cervical or lumbar radiculopathy with neurologic deficit (work up first)
  • Suspected systemic inflammatory disorder (polymyalgia rheumatica, inflammatory myopathy)
  • Fibromyalgia primary diagnosis (separate condition page; different protocol)

Related Conditions

References

  • [B1]

    Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]

    Москва: Монолит(2004)https://search.rsl.ru/ru/record/01007959553

    Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.

  • [B3]

    Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy

    Stuttgart — New York: Thieme(2007)https://books.google.com/books?vid=ISBN9781588905635

    ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.

The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.